Science Explorer Interactive view Map
Company · St Louis · United States

Aclaris Therapeutics (United States)

Research works
22
▲ 1424% vs 2013–17
Citations
255
11.8 per fractional work
Top-10% rate
0.0%
record average 16.5%
Open access
39%
world 28%

Not ranked overall: Aclaris Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Which keywords describe research at Aclaris Therapeutics (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer, Cancer Therapy, Immune Response, Inflammation, Cell Proliferation, Immunotherapy, Immunity and Gene Therapy.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 34 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 34 words, with their numbers
  1. Cancer4▲ 12×11 topics
  2. Cancer Therapy3▲ 22×6 topics
  3. Inflammation3▲ 5.7×11 topics
  4. Immune Response3▲ 20×5 topics
  5. Epidemiology2▲ 2.6×11 topics
  6. Cell Proliferation2▲ 102×2 topics
  7. Immunity2▲ 25×5 topics
  8. Immunotherapy2▲ 13×5 topics
  9. Gene Therapy2▲ 30×3 topics
  10. Melanoma2▲ 156×2 topics
  11. Oncogenic Mutations2▲ 147×2 topics
  12. Diagnosis1▲ 6.2×3 topics
  13. Tumor Microenvironment1▲ 19×3 topics
  14. Autoantibodies1▲ 26×2 topics
  15. Autoimmune1▲ 119×2 topics
  16. BRAF gene1▲ 348×1 topic
  17. Innate Immunity1▲ 17×4 topics
  18. MAP Kinase1▲ 348×1 topic
  19. Cancer Immunotherapy1▲ 38×3 topics
  20. Medicinal Chemistry1▲ 15×4 topics
  21. Tumor Regression1▲ 62×2 topics
  22. Anticancer Agents1▲ 21×2 topics
  23. Catalysis1▲ 6.2×2 topics
  24. Immunosuppressive Therapy1▲ 26×2 topics
  25. NF-?B Activation1▲ 94×2 topics
  26. Rituximab1▲ 31×2 topics
  27. Synthesis1▲ 8.4×1 topic
  28. Tetrazoles1▲ 848×1 topic
  29. Bullous Pemphigoid1▲ 169×1 topic
  30. Epigenetic Regulation1▲ 21×2 topics
  31. Pemphigoid1▲ 169×1 topic
  32. Proteasome1▲ 116×1 topic
  33. Tumor Targeting1▲ 35×2 topics
  34. Ubiquitin1▲ 116×1 topic

Which research topics does Aclaris Therapeutics (United States) publish most on?

By volume in 2022–2025: Synthesis of Tetrazole Derivatives, Cancer Immunotherapy and Biomarkers, Cancer Research and Treatments and Cancer Cells and Metastasis.

  1. 1 Synthesis of Tetrazole Derivatives Organic Chemistry 1 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
  3. 3 Cancer Research and Treatments Biotechnology 0 works
  4. 4 Cancer Cells and Metastasis Oncology 0 works
  5. 5 Immune cells in cancer Immunology 0 works
  6. 6 Inflammasome and immune disorders Molecular Biology 0 works
  7. 7 Biomarkers in Disease Mechanisms Immunology 0 works
  8. 8 Cancer-related gene regulation Molecular Biology 0 works
  9. 9 Melanoma and MAPK Pathways Molecular Biology 0 works
  10. 10 Cancer-related Molecular Pathways Oncology 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available38.6%not open61.4%

World: 28% of research is openly available.

with international co-authors7.4%domestic only92.6%

World: 19% is written across borders.

How has Aclaris Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 1424% higher than in 2013–2017.

20152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in St Louis

All research institutions in St Louis

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.